UBS Group’s Labcorp LH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$151M Buy
564,529
+68,994
+14% +$18.7M 0.02% 768
2025
Q4
$124M Buy
495,535
+10,506
+2% +$2.79M 0.02% 860
2025
Q3
$139M Sell
485,029
-12,401
-2% -$3.32M 0.02% 798
2025
Q2
$131M Buy
497,430
+55,790
+13% +$13.6M 0.02% 779
2025
Q1
$103M Buy
441,640
+53,918
+14% +$13.1M 0.02% 912
2024
Q4
$88.9M Buy
387,722
+21,398
+6% +$4.91M 0.02% 996
2024
Q3
$81.9M Sell
366,324
-17,675
-5% -$3.88M 0.02% 842
2024
Q2
$78.1M Sell
383,999
-86,124
-18% -$17.5M 0.02% 765
2024
Q1
$103M Buy
470,123
+66,298
+16% +$14.6M 0.03% 633
2023
Q4
$91.8M Sell
403,825
-28,301
-7% -$5.95M 0.03% 614
2023
Q3
$86.9M Sell
432,126
-59,376
-12% -$12.5M 0.03% 554
2023
Q2
$102M Buy
491,502
+11,928
+2% +$2.31M 0.03% 490
2023
Q1
$94.5M Buy
479,574
+82,430
+21% +$17M 0.03% 479
2022
Q4
$80.3M Buy
397,144
+48,283
+14% +$9.44M 0.03% 579
2022
Q3
$61.4M Sell
348,861
-26,147
-7% -$5.35M 0.03% 601
2022
Q2
$75.5M Sell
375,008
-32,422
-8% -$6.91M 0.03% 543
2022
Q1
$92.3M Sell
407,430
-58,388
-13% -$13.7M 0.03% 548
2021
Q4
$126M Buy
465,818
+16,505
+4% +$4.09M 0.04% 509
2021
Q3
$109M Buy
449,313
+24,448
+6% +$6.16M 0.03% 505
2021
Q2
$101M Buy
424,865
+373
+0.1% +$85K 0.03% 517
2021
Q1
$93M Sell
424,492
-6,074
-1% -$1.22M 0.03% 547
2020
Q4
$75.3M Buy
430,566
+34,188
+9% +$5.91M 0.03% 585
2020
Q3
$64.1M Sell
396,378
-1,810
-0.5% -$287K 0.02% 552
2020
Q2
$56.8M Buy
398,188
+5,826
+1% +$806K 0.02% 550
2020
Q1
$42.6M Sell
392,362
-77,370
-16% -$11.1M 0.02% 611
2019
Q4
$68.3M Buy
469,732
+37,605
+9% +$5.43M 0.02% 597
2019
Q3
$62.4M Buy
432,127
+51,563
+14% +$7.52M 0.02% 577
2019
Q2
$56.5M Buy
380,564
+166,261
+78% +$23.2M 0.02% 617
2019
Q1
$28.2M Buy
214,303
+23,541
+12% +$2.9M 0.01% 944
2018
Q4
$20.7M Sell
190,762
-53,673
-22% -$7.19M 0.01% 1057
2018
Q3
$36.5M Buy
244,435
+49,903
+26% +$7.59M 0.01% 832
2018
Q2
$30M Buy
194,532
+21,648
+13% +$3.27M 0.01% 928
2018
Q1
$24M Sell
172,884
-11,491
-6% -$1.69M 0.01% 1026
2017
Q4
$25.3M Buy
184,375
+44,849
+32% +$5.93M 0.01% 1041
2017
Q3
$18.1M Buy
139,526
+50,424
+57% +$6.73M 0.01% 1162
2017
Q2
$11.8M Sell
89,102
-16,580
-16% -$2.03M 0.01% 1408
2017
Q1
$13M Buy
105,682
+16,133
+18% +$1.91M 0.01% 1296
2016
Q4
$9.88M Sell
89,549
-14,389
-14% -$1.6M 0.01% 1506
2016
Q3
$12.3M Sell
103,938
-16,333
-14% -$1.92M 0.01% 1275
2016
Q2
$13.5M Sell
120,271
-752,599
-86% -$81M 0.01% 1191
2016
Q1
$87.8M Buy
872,870
+419,799
+93% +$40.2M 0.06% 303
2015
Q4
$48.1M Buy
453,071
+335,581
+286% +$34.6M 0.03% 522
2015
Q3
$10.9M Buy
117,490
+26,838
+30% +$2.78M 0.01% 1306
2015
Q2
$9.44M Sell
90,652
-11,633
-11% -$1.21M 0.01% 1527
2015
Q1
$11.1M Buy
102,285
+1,291
+1% +$133K 0.01% 1397
2014
Q4
$9.36M Buy
+100,994
New +$8.92M 0.01% 1554

Other funds holding LH

UBS Group's LH Position: Q1 2026 in Review

UBS Group increased its Labcorp (LH) stake by 14% in Q1 2026, buying an estimated $18.7M and bringing the position to 564,529 shares worth $151M. The position accounts for 0.02% of the portfolio, ranked #768.

UBS Group first reported a position in LH in Q4 2014 and has held it in 46 quarters since. 1,031 funds tracked by Wall St. Rank hold LH as of Q1 2026.

  • UBS Group held 564,529 shares of Labcorp worth $151M as of Q1 2026.
  • UBS Group bought 68,994 Labcorp shares in Q1 2026, an estimated $18.7M.
  • Labcorp made up 0.02% of UBS Group's portfolio in Q1 2026, its #768 holding.
  • UBS Group first reported a position in Labcorp in Q4 2014 and has held it in 46 quarters since.
  • 1,031 funds tracked by Wall St. Rank held Labcorp as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.